Scenesse Approval Buoys Clinuvel As It Fights Retrophin
This article was originally published in PharmAsia News
The Australian firm Clinuvel sees good prospects for its dermatology product Scenesse, but at the same time is fighting off unwanted acquisition advances from a corporate suitor.
You may also be interested in...
The latest drug development news and highlights from our US FDA Performance Tracker.
Europe’s top medicines advisory panel, the CHMP, also recommended for approval Clinuvel’s Scenesse for severe intolerance to sunlight, Pfizer’s new combination menopausal symptom therapy Duavive, and Baxter’s new hemophilia B therapy Rixubis.
Cynata has inched closer to a major global partnership after signing a term sheet with Fujifilm for cell therapy technologies that has been described by analysts as a potentially transformative deal.